Want to see IN:APLLTD full AI Analyst Report?
Alembic Pharmaceuticals Limited (APLLTD) AI Stock Analysis
Alembic Pharmaceuticals Limited
(NSE:APLLTD)
Bullish technical momentum above key moving averages and a stable low-leverage balance sheet are the main positives, tempered by cash flow inconsistencies and fair valuation.
Alembic Pharmaceuticals Limited (APLLTD) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 156.83B
- Dividend Yield
- 1.50%
- Average Volume (3M)
- 21.65K
- Price to Earnings (P/E)
- 22.6
- Beta (1Y)
- 1.08
- Revenue Growth
- 14.12%
- EPS Growth
- 14.98%
- Country
- India
- Employees
- 17,244
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
Alembic Pharmaceuticals Limited Business Overview & Revenue Model
Company Description
Alembic Pharmaceuticals Limited is a pharmaceutical firm that develops, manufactures, and markets medicinal products both domestically in India and across international markets. Its offerings encompass active pharmaceutical ingredients (APIs) and a w...
How the Company Makes Money
Alembic Pharmaceuticals makes money primarily by selling pharmaceutical products across domestic and international markets, with revenue generated from multiple streams: (1) Formulations (finished dosage medicines): The company earns revenue by manuf...
Alembic Pharmaceuticals Limited Financial Statement Overview
Summary
Steady revenue growth from 53.9B to 73.4B is supported by a stable balance sheet with low debt-to-equity, but fluctuating net income and inconsistent cash flows due to margin pressures indicate only moderate financial health.
Income Statement
65PositiveBalance Sheet
75PositiveCash Flow
55Neutral| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 77.84B | 73.45B | 66.72B | 62.29B | 56.53B | 53.06B |
| Gross Profit | 34.61B | 33.10B | 47.91B | 44.33B | 38.78B | 38.08B |
| EBITDA | 11.66B | 11.06B | 10.08B | 9.33B | 7.13B | 8.74B |
| Net Income | 6.93B | 6.75B | 5.83B | 6.16B | 3.42B | 5.21B |
Balance Sheet | ||||||
| Total Assets | 0 | 87.63B | 77.73B | 64.46B | 61.83B | 71.22B |
| Cash, Cash Equivalents and Short-Term Investments | 1.96B | 2.03B | 901.00M | 1.20B | 754.80M | 610.90M |
| Total Debt | 0 | 14.30B | 12.57B | 5.13B | 7.22B | 7.17B |
| Total Liabilities | -56.69B | 30.94B | 25.83B | 16.27B | 18.12B | 18.84B |
| Stockholders Equity | 56.69B | 56.75B | 51.91B | 48.18B | 43.70B | 52.38B |
Cash Flow | ||||||
| Free Cash Flow | 1.69B | 2.61B | -4.76B | 4.76B | 2.81B | 1.27B |
| Operating Cash Flow | 4.03B | 6.95B | 879.70M | 8.03B | 7.24B | 5.52B |
| Investing Cash Flow | -2.87B | -5.07B | -5.68B | -3.21B | -4.48B | -3.72B |
| Financing Cash Flow | -649.70M | -756.50M | 4.44B | -4.38B | -2.62B | -2.17B |
Alembic Pharmaceuticals Limited Peers Comparison
Overall Rating
IN:ALIVUS86Outperform
IN:NATCOPHARM74Outperform- IN:APLLTD68Neutral
IN:GRANULES64Neutral
IN:PPLPHARMA56Neutral
IN:JUBLPHARMA45Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| IN:ALIVUS | 86Outperform | INR 172.84B | 25.95 | ― | 0.36% | 8.19% | 26.12% |
| IN:NATCOPHARM | 74Outperform | INR 153.50B | 12.25 | ― | 0.57% | -20.73% | -32.59% |
| IN:APLLTD | 68Neutral | INR 156.82B | 22.62 | ― | 1.50% | 14.12% | 14.98% |
| IN:GRANULES | 64Neutral | INR 208.04B | 31.03 | ― | 0.21% | 24.83% | 36.88% |
| IN:PPLPHARMA | 56Neutral | INR 318.26B | -151.42 | ― | 0.06% | 9.43% | -767.49% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| IN:JUBLPHARMA | 45Neutral | INR 147.29B | 41.54 | ― | 0.54% | 16.27% | -23.50% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:APLLTD | Alembic Pharmaceuticals Limited | 797.80 | -148.22 | -15.67% | |
| IN:ALIVUS | Glenmark Life Sciences Limited | 1407.80 | 505.38 | 56.00% | |
| IN:GRANULES | Granules India Limited | 839.55 | 273.28 | 48.26% | |
| IN:JUBLPHARMA | Jubilant Pharmova Limited | 924.70 | -250.47 | -21.31% | |
| IN:NATCOPHARM | NATCO Pharma Limited | 782.50 | -26.81 | -3.31% | |
| IN:PPLPHARMA | Piramal Pharma Limited | 239.05 | 38.55 | 19.23% |
Alembic Pharmaceuticals Limited Corporate Events
Alembic Pharmaceuticals Sets August 5 Virtual AGM, Announces E-Voting and Dividend Record Date
Alembic Pharmaceuticals has notified exchanges and shareholders that its 16th Annual General Meeting will be held on August 5, 2026, via video conferencing and other audio-visual means, in line with provisions of the Companies Act and SEBI listing re...
Alembic Pharma Schedules One-on-One Meets With Key Institutional Investors
Alembic Pharmaceuticals has disclosed that its management will hold a series of one-on-one meetings with key institutional investors, including HDFC Mutual Fund, Tata Mutual Fund, DSP Mutual Fund, and HDFC Life Insurance Company, between June 22 and...
Alembic Pharmaceuticals Plans One-on-One Meets With Key Institutional Investors
Alembic Pharmaceuticals has scheduled a series of one-on-one investor meetings with major institutional investors, including HDFC Mutual Fund, Tata Mutual Fund, DSP Mutual Fund, and HDFC Life Insurance Company. The meetings, to be held in Mumbai and...
Alembic Pharmaceuticals Lines Up One-on-One Meetings With Key Institutional Investors
Alembic Pharmaceuticals has scheduled one-on-one investor meetings with major institutional investors, including HDFC Mutual Fund, Tata Mutual Fund, DSP Mutual Fund, and HDFC Life Insurance Company. The meetings, to be held in Mumbai and via video co...
Alembic Pharma Sets Virtual AGM, Record Date and Updates Dividend, KYC, and TDS Rules
Alembic Pharmaceuticals has announced that its 16th Annual General Meeting will be held on 5 August 2026 at 4:00 p.m. IST via video conferencing or other audio-visual means, in line with provisions of the Companies Act and SEBI listing regulations. T...
Alembic Pharma Takes 45% Stake in New Canadian Drug Venture
Alembic Pharmaceuticals Limited has signed a shareholders’ agreement to invest in a newly incorporated Canadian company, 17989377 Canada Inc., alongside Difgen Holdings LLC and another minority investor. Alembic and Difgen will each hold a 45%...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 19, 2026